Literature DB >> 10787000

Improvement in HIV-associated motor slowing after antiretroviral therapy including protease inhibitors.

N C Sacktor1, R L Skolasky, R H Lyles, D Esposito, O A Selnes, J C McArthur.   

Abstract

A study of neuropsychological performance was conducted in 33 HIV+ patients initiating highly active antiretroviral therapy (HAART). Grooved Pegboard (GP) non-dominant hand performance improved in 23/33 (70%) subjects (P=0.002). Among 23 patients with motor slowing (GP non-dominant hand z score < -1.0) at baseline, 18 (78%) improved on the GP non-dominant hand test after initiating HAART (P=0.001). GP non-dominant hand performance improved longitudinally in HIV+ patients initiating HAART, while matched HIV+ controls not on HAART did not change (P=0.045). Significant improvement in motor performance can occur after HAART in HIV+ patients with impairment.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10787000     DOI: 10.3109/13550280009006385

Source DB:  PubMed          Journal:  J Neurovirol        ISSN: 1355-0284            Impact factor:   2.643


  30 in total

Review 1.  Human immunodeficiency virus-associated dementia: an evolving disease.

Authors:  Justin C McArthur; Norman Haughey; Suzanne Gartner; Kathy Conant; Carlos Pardo; Avi Nath; Ned Sacktor
Journal:  J Neurovirol       Date:  2003-04       Impact factor: 2.643

Review 2.  Young onset dementia.

Authors:  E L Sampson; J D Warren; M N Rossor
Journal:  Postgrad Med J       Date:  2004-03       Impact factor: 2.401

3.  Reward, attention, and HIV-related risk in HIV+ individuals.

Authors:  Brian A Anderson; Sharif I Kronemer; Jessica J Rilee; Ned Sacktor; Cherie L Marvel
Journal:  Neurobiol Dis       Date:  2015-10-17       Impact factor: 5.996

4.  Neuroprotective and antiretroviral effects of the immunophilin ligand GPI 1046.

Authors:  Joseph P Steiner; David Galey; Norman J Haughey; Daniella Asch; Avindra Nath
Journal:  J Neuroimmune Pharmacol       Date:  2007-01-03       Impact factor: 4.147

5.  Regional cortical thinning associated with detectable levels of HIV DNA.

Authors:  Kalpana J Kallianpur; Gregory R Kirk; Napapon Sailasuta; Victor Valcour; Bruce Shiramizu; Beau K Nakamoto; Cecilia Shikuma
Journal:  Cereb Cortex       Date:  2011-10-19       Impact factor: 5.357

6.  Second assessment of NeuroAIDS in Africa.

Authors:  Kevin Robertson; Kathy Kopnisky; James Hakim; Concepta Merry; Noeline Nakasujja; Colin Hall; Moussa Traore; Ned Sacktor; David Clifford; Charles Newton; Annelies Van Rie; Penny Holding; Janice Clements; Christine Zink; Jens Mielk; Mina Hosseinipour; Umesh Lalloo; Farida AMod; Christina Marra; Scott Evans; Jeff Liner
Journal:  J Neurovirol       Date:  2008-04       Impact factor: 2.643

Review 7.  Does highly active antiretroviral therapy improve neurocognitive function? A systematic review.

Authors:  John A Joska; Hetta Gouse; Robert H Paul; Dan J Stein; Alan J Flisher
Journal:  J Neurovirol       Date:  2010-03       Impact factor: 2.643

8.  The recombinant vaccinia virus gene product, B18R, neutralizes interferon alpha and alleviates histopathological complications in an HIV encephalitis mouse model.

Authors:  Cari Fritz-French; Ramzi Shawahna; Jennifer E Ward; Leonard E Maroun; William R Tyor
Journal:  J Interferon Cytokine Res       Date:  2014-02-24       Impact factor: 2.607

9.  Impact of short-term combined antiretroviral therapy on brain virus burden in simian immunodeficiency virus-infected and CD8+ lymphocyte-depleted rhesus macaques.

Authors:  Lakshmanan Annamalai; Veena Bhaskar; Douglas R Pauley; Heather Knight; Kenneth Williams; Margaret Lentz; Eva Ratai; Susan V Westmoreland; R Gilberto González; Shawn P O'Neil
Journal:  Am J Pathol       Date:  2010-07-01       Impact factor: 4.307

10.  Normative scores for a brief neuropsychological battery for the detection of HIV-associated neurocognitive disorder (HAND) among South Africans.

Authors:  Dinesh Singh; John A Joska; Karl Goodkin; Enrique Lopez; Landon Myer; Robert H Paul; Sally John; Henry Sunpath
Journal:  BMC Res Notes       Date:  2010-01-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.